drugset

drugset / Trial / NCT05337345

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

NCT05337345 ↗

Phase 1 Completed 104 enrolled Bristol-Myers Squibb

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug levels of cendakimab delivered subcutaneously in healthy participants.

Timeline

Start: 2022-05-02
Primary completion: 2022-12-15
Completion: 2022-12-15

Publications

Zhang P, De Oliveira CHMC, Yu K, Basdeo S, Charriez CM, Syto M, Thomas M, Murthy B. Pharmacokinetic Characterization of Cendakimab Administered with Different Devices and at Different Injection Sites in Healthy Participants. Eur J Drug Metab Pharmacokinet. 2025 Jul;50(4):307-317. doi: 10.1007/s13318-025-00949-0. Epub 2025 May 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cendakimab	Monoclonal antibody	360 mg	Subcutaneous

Indications

No indication recorded.